Table 2.

Multivariate analyses of freedom from biochemical relapse

Variable		n	HR	95% CI	P
Patient age	≤64	418	1.000	(ref)	—
	65–69	352	0.687	0.474–0.996	0.047
	70–74	359	0.427	0.279–0.653	<0.001
	≥75	246	0.465	0.295–0.733	0.001
T classification	T1	820	1.000	(ref)	—
	T2	341	1.696	1.138–2.528	0.009
	T3‐4	214	1.911	1.191–3.064	0.007
Percentage of positive cores (%)	0–24	516	1.000	(ref)	—
	25–49	451	1.905	1.208–3.003	0.006
	50–74	273	2.298	1.390–3.797	0.001
	75–100	135	2.854	1.642–4.961	<0.001
Gleason Score	≤ 6	426	1.000	(ref)	–
	7	668	0.999	0.653–1.529	0.997
	≥8	281	1.739	1.075–2.815	0.024
PSA (ng/ml)	<10.0	769	1.000	(ref)	–
	10.0–20.0	342	2.114	1.432–3.120	<0.001
	>20.0	264	2.408	1.531–3.789	<0.001
Total ADT (month)	≥6	699	0.697	0.474–1.025	0.067

PSA, prostate‐specific antigen; ADT, androgen deprivation therapy.